MidWestOne Financial Group Inc. Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

MidWestOne Financial Group Inc. lifted its position in Pfizer Inc. (NYSE:PFE) by 1.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,530 shares of the biopharmaceutical company’s stock after buying an additional 386 shares during the quarter. MidWestOne Financial Group Inc.’s holdings in Pfizer were worth $742,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Gilbert & Cook Inc. increased its position in shares of Pfizer by 3.8% in the fourth quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 945 shares during the last quarter. Gryphon Financial Partners LLC increased its position in shares of Pfizer by 43.7% in the fourth quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company’s stock worth $861,000 after purchasing an additional 8,194 shares during the last quarter. Evoke Wealth LLC increased its position in shares of Pfizer by 14.4% in the fourth quarter. Evoke Wealth LLC now owns 44,427 shares of the biopharmaceutical company’s stock worth $1,279,000 after purchasing an additional 5,597 shares during the last quarter. Tradition Wealth Management LLC increased its position in shares of Pfizer by 18.2% in the fourth quarter. Tradition Wealth Management LLC now owns 16,791 shares of the biopharmaceutical company’s stock worth $483,000 after purchasing an additional 2,583 shares during the last quarter. Finally, Alberta Investment Management Corp increased its position in shares of Pfizer by 20.9% in the fourth quarter. Alberta Investment Management Corp now owns 186,375 shares of the biopharmaceutical company’s stock worth $5,366,000 after purchasing an additional 32,175 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of PFE stock opened at $29.09 on Friday. The stock has a fifty day moving average of $29.31 and a 200 day moving average of $28.29. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $34.11. The firm has a market capitalization of $164.84 billion, a price-to-earnings ratio of -484.75, a PEG ratio of 1.27 and a beta of 0.68. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same quarter last year, the firm posted $0.67 earnings per share. The firm’s revenue was up 2.1% on a year-over-year basis. As a group, research analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent research reports. Wells Fargo & Company increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, September 16th. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Finally, StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.